This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PR-957
Description: ONX 0914 is being developed to be an inhibitor of the immunoproteasome, with minimal cross-reactivity for the constitutive proteasome. Recent evidence suggests that the immunoproteasome regulates the production of several inflammatory cytokines, including Tumor Necrosis Factor-alpha(TNF-alpha), Interleukin-6 (IL-6), IL-17, and IL-23.
Onyx and Proteolix
ONX 0914 (PR-957) was originally developed by Proteolix.
In October 2009, Onyx Pharmaceuticals announced that it signed a definitive agreement to acquire Proteolix. This acquisition completed in November 2009.
Onyx and Amgen
In August 2013, Amgen and Onyx announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Amgen intends to effect the transaction through a tender offer.
In October 2013, Amgen announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx for $125 per share in cash. As announced on August 25, the purchase price is $9.7 billion net of estimated Onyx cash. The tender offer expired at 12:00 midnight New York City time on Oct. 1, 2013....See full deal structure in Biomedtracker
ONX 0914 News
Additional information available to subscribers only: